However, patients with low BSA psoriasis and burdensome symptoms who are candidates for biologic therapy (according to the clinicians judgement) may not meet a payers criteria for eligibility to receive advanced psoriasis treatment options [4, 9, 23, 28] Current International Psoriasis Council (IPC), American Academy of Dermatology, and National Psoriasis Foundation treatment guidelines recommend that indicators of psoriasis disease burden beyond BSA, including involvement of high-impact sites and failure of topical therapies, be considered when determining whether patients are eligible for systemic treatment [3, 4]
Share your experience or ask your questions in the comments below
Benefcios: Contm L-carnitina, quitosana, cromo e vitamina C Auxilia no metabolismo de protenas, carboidratos e gorduras Contribui para o metabolismo energtico Suporte para uma rotina de exerccios e alimentao equilibrada Frmula prtica em cpsulas para consumo dirio Apresentao: Frasco com 60 cpsulas de 550 mg
Microsc Res Tech (2000) 50:18495
